Pivotal Data For the Treatement of XLRP

Show Description +

Dr. Sisk provides an update on the VISTA trial of laru-zova (Beacon Therapeutics), a subretinal gene therapy for X-linked retinitis pigmentosa. The trial met it's primary endpoint with a significant portion of patients achieving 3 or more lines of low-luminance visual acuity.

Posted: 10/15/2026

Keywords:

VISTA

•

Clinical Trials

•

laru-zova

•

Beacon Therapeutics

•

Subretinal

•

Gene Therapy

•

x-linked

•

Retinitis pigmentosa

•

low-luminance

•

Visual Acuity

•

retina-meeting-recap

•

Retina Subspecialty Day

Up Next

Name: Pivotal Data For the Treatement of XLRP
Uploaded: 2026-10-15T19:23:20+00:00
Description: Dr. Sisk provides an update on the VISTA trial of laru-zova (Beacon Therapeutics), a subretinal gene therapy for X-linked retinitis pigmentosa. The trial met it's primary endpoint with a significant portion of patients achieving 3 or more lines of low-luminance visual acuity.

Gene Therapy for GA: ArMaDa Trial Update

Raj K. Maturi, MD

An Ophthalmologist’s Evolving Collaboration With Neurosurgery

Kyle J. Godfrey, MD, FACS

Highlights From This Year’s Cornea Literature

Divya Srikumaran, MD

Considerations for Monovision and Mini-Monovision Approaches

Nandini Venkateswaran, MD

$Exploring the Frontiers of Refractive Surgery$

Exploring the Frontiers of Refractive Surgery

Julie Schallhorn, MD, MS

Customized CAIRS for Post-LASIK Ectasia

Soosan Jacob, MD

Three Lessons for Glaucoma Graduates

David Fleischman, MD, MS, FACS

Taking the Leap Toward VR Perimetry

Matthew Brink, MD

Reliable IOP Measurements With the iCare Tonometer

Sanjay Asrani, MD

High-Tech Solutions for Low Vison

Sharon Fekrat, MD, FACS

The Gene Therapy Pipeline for AMD

Allen C. Ho, MD

First-Time Phase 2 Data for Sura-Vec in DME

Arshad M. Khanani, MD

Repairing TRDs in the Retina OR

Maria H. Berrocal, MD

Complement Inhibitors in Practice: Longer-Term Findings

Sunir J. Garg, MD, FACS

Sickle Cell Retinopathy: An Update on Screening and Care

Adrienne Williams Scott, MD

Novel Approaches to Measuring GA Progression

SriniVas R. Sadda, MD

Positive Phase 3 Data for Tarcocimab

Charles C. Wykoff, MD, PhD

Inflammasome Inhibitor Moving Through the Pipeline

Liangbo Linus Shen, MD

Back to All Videos

Pivotal Data For the Treatement of XLRP

Robert A. Sisk MD

Posted: 10/15/2026

Keywords:

VISTA

•

Clinical Trials

•

laru-zova

•

Beacon Therapeutics

•

Subretinal

•

Gene Therapy

•

x-linked

•

Retinitis pigmentosa

•

low-luminance

•

Visual Acuity

•

retina-meeting-recap

•

Retina Subspecialty Day

Read Transcript

Hi, I'm Dr. Robert Sisk from the Cincinnati Eye Institute, and I just presented at the American Academy of Ophthalmology, meeting the top line results from Beacon's phase three study, VISTA, using subretinal LARA-ZOVA gene therapy for X-linked retinitis pigmentosa. This was a phase two / three multicenter randomized controlled clinical trial comparing two dose levels of LARAZOVA to untreated controls. The study met its primary endpoint with a significant proportion of patients achieving three or more lines of gain of low luminance visual acuity compared to controls. Also, microperimetry improved across treated patients compared to the control group. With these positive top line results, Beacon plans to file a rolling BLA submission later this year.

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Pivotal Data For the Treatement of XLRP

Up Next

Pivotal Data For the Treatement of XLRP

More From AAO: 2026 Coverage